AbCellera Biologics (ABCL) Invested Capital (2020 - 2026)

AbCellera Biologics has reported Invested Capital for 7 years, with the latest figure at $938.1 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 9.08% year-over-year to $938.1 million; the trailing twelve-month figure through Mar 2026 stood at $938.1 million (down 9.08% YoY), and the FY2025 full-year result was $966.9 million, down 9.14% from the prior year.
• Invested Capital for Q1 2026 stood at $938.1 million, down from $966.9 million in the prior quarter.
• The five-year high for Invested Capital was $1.3 billion in Q3 2022, with the low at $938.1 million in Q1 2026.
• Historically, Invested Capital has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2024.
• Annual changes were most pronounced in 2022 — Invested Capital jumped 32.85% — and 2025, when it slipped 12.66%.
• AbCellera Biologics' Invested Capital stood at $1.3 billion in 2022, then dropped by 5.85% to $1.2 billion in 2023, then fell by 11.53% to $1.1 billion in 2024, then declined by 9.14% to $966.9 million in 2025, then declined by 2.98% to $938.1 million in 2026.
• The last three Invested Capital figures came in at $938.1 million (Q1 2026), $966.9 million (Q4 2025), and $964.0 million (Q3 2025), per Business Quant data.